Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) has announced significant progress on its Ibogaine Initiative, securing naturally derived ibogaine from two sources in both hydrochloride and freebase forms. The company expects development of finished ibogaine drug products to begin this summer at its GMP-certified manufacturing facility in British Columbia, with plans to produce standardized 50 mg and 100 mg encapsulated dosage formats for research and regulated access programs.
The update comes amid growing interest in ibogaine research and expanding public funding for psychedelic therapies, including a recently announced $50 million program in Texas. Optimi said its development program will include formulation, manufacturing validation, analytical testing and packaging processes, leveraging the same GMP infrastructure currently used to produce psilocybin and MDMA products. Management believes Canada’s regulatory framework and the company’s existing licenses position Optimi to support increasing demand for GMP-grade ibogaine for clinical research and potential therapeutic applications.
Optimi Health Corp. is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada. Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country’s Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.
This announcement matters because it signals a tangible step toward standardizing ibogaine for clinical research, which has historically been hampered by inconsistent sourcing and lack of regulatory-grade product. By producing GMP-grade ibogaine in encapsulated formats, Optimi could facilitate more rigorous studies and potentially accelerate the pathway to regulated therapeutic use. The timing aligns with increased public investment, such as Texas’ $50 million psychedelic research program, suggesting that ibogaine may play a role in the evolving mental health treatment landscape.
For the industry, Optimi’s move could set a precedent for how ibogaine is developed and supplied, similar to the company’s established role with psilocybin and MDMA. For readers, particularly those tracking psychedelic medicine access, this development may indicate that ibogaine, long associated with addiction treatment in underground settings, is moving toward mainstream clinical evaluation. The implications extend to investors as well, as standardized production could open new markets and regulatory pathways.
To view the full press release, visit https://ibn.fm/IAz1L.
